The novel, specific small molecule plasma kallikrein inhibitor ASP-440 normalizes retinal vascular permeability in streptozotocin-induced diabetes
The novel, specific small molecule plasma kallikrein inhibitor ASP-440 normalizes retinal vascular permeability in streptozotocin-induced diabetes. ADA. 2010.